Menlo Therapeutics Inc is a US-based late-stage biopharmaceutical company which focuses on the development and commercialization of Serlopitant for the treatment of pruritus associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The pipeline product of the company includes Prurigo Nodularis, Prurigo Dermatitis, Psoriasis and Refractory Chronic Cough.
